NCT04875611View on ClinicalTrials.gov

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Nasopharyngeal Cancer
Interventions
DRUG

Opdivo

Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).

Trial Locations (4)

Unknown

RECRUITING

Klinika Hematologii z Pododziałem Chorób Naczyń Uniwersyteckiego Szpitala Klinicznego w Białymstoku, Bialystok

RECRUITING

Klinika Hematologii i Transplantologii Gdańskiego Uniwersytetu Medycznego, Gdansk

RECRUITING

Klinika Hematologii i Transplantacji Szpiku, Świętokrzyskie Centrum Onkologii, Kielce

44-101

RECRUITING

Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach, Gliwice

Sponsors

Collaborators (1)

KCRI
All Listed Sponsors
collaborator

KCRI

OTHER

lead

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER

NCT04875611 - Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment | Biotech Hunter | Biotech Hunter